[go: up one dir, main page]

MX2016013201A - Composicion y metodo para producir una nanoformulacion de bioactivos insolubles en agua en una base acuosa. - Google Patents

Composicion y metodo para producir una nanoformulacion de bioactivos insolubles en agua en una base acuosa.

Info

Publication number
MX2016013201A
MX2016013201A MX2016013201A MX2016013201A MX2016013201A MX 2016013201 A MX2016013201 A MX 2016013201A MX 2016013201 A MX2016013201 A MX 2016013201A MX 2016013201 A MX2016013201 A MX 2016013201A MX 2016013201 A MX2016013201 A MX 2016013201A
Authority
MX
Mexico
Prior art keywords
nanodispersion
nanoformulation
bioactives
producing
composition
Prior art date
Application number
MX2016013201A
Other languages
English (en)
Inventor
DEVRAJ Rambhau
CHHATOI Pranati
Hemanth Kumar PARVATHABHATLA Naga
Vasant Deshmukh Anand
Kaushik CHINTABHATLA Krishna
Original Assignee
Nanoceutica Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanoceutica Laboratories Pvt Ltd filed Critical Nanoceutica Laboratories Pvt Ltd
Publication of MX2016013201A publication Critical patent/MX2016013201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Colloid Chemistry (AREA)

Abstract

La modalidad ejemplar de la presente exposición se dirige hacia una nanodispersión estable que comprende un medio de dispersión acuosa, una fase dispersa, un agente tensoactivo y opcionalmente, un aditivo, en donde el medio de dispersión acuosa comprende un componente base de vehículo estabilizador de nanodispersión, en donde el componente base de vehículo estabilizador de nanodispersión mejora la estabilidad física a largo plazo de la nanodispersión con o sin reducción del tamaño de partícula, en donde la fase dispersa comprende un compuesto bioactivo y en donde el compuesto bioactivo es lipofílico e hidrofóbico. Otra modalidad ejemplar de la presente exposición se dirige hacia un método de preparación de tal nanodispersión estable.
MX2016013201A 2014-04-09 2015-04-08 Composicion y metodo para producir una nanoformulacion de bioactivos insolubles en agua en una base acuosa. MX2016013201A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1872CH2014 IN2014CH01872A (es) 2014-04-09 2015-04-08
PCT/IB2015/052541 WO2015155703A2 (en) 2014-04-09 2015-04-08 Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base

Publications (1)

Publication Number Publication Date
MX2016013201A true MX2016013201A (es) 2017-04-25

Family

ID=54288490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013201A MX2016013201A (es) 2014-04-09 2015-04-08 Composicion y metodo para producir una nanoformulacion de bioactivos insolubles en agua en una base acuosa.

Country Status (7)

Country Link
US (1) US11458096B2 (es)
EP (1) EP3129002A4 (es)
AU (1) AU2015246030B2 (es)
EA (1) EA038458B1 (es)
IN (1) IN2014CH01872A (es)
MX (1) MX2016013201A (es)
WO (1) WO2015155703A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014393037B2 (en) 2014-04-30 2019-02-28 Matoke Holdings Limited Antimicrobial compositions
GB201716986D0 (en) 2017-10-16 2017-11-29 Matoke Holdings Ltd Antimicrobial compositions
FR3075661A1 (fr) * 2017-12-21 2019-06-28 Coatex Emulsion submicronique
WO2019133785A1 (en) * 2017-12-29 2019-07-04 L'oreal Compositions for altering the color of hair
WO2019175830A1 (en) * 2018-03-14 2019-09-19 Azista Industries Pvt Ltd Cholecalciferol nanoemulsion formulations and methods for producing same
WO2023118928A1 (en) 2021-12-21 2023-06-29 Opella Healthcare Group Sas Stable nanoformulation for lipophilic actives, oral dosage form and process for its preparation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507172A (ja) * 1991-04-19 1994-08-11 アフィニティー　バイオテック，インコーポレイテッド 転換可能なミクロエマルジョン処方剤
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
WO1997010814A1 (en) * 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
DE19642359A1 (de) 1996-10-14 1998-04-16 Basf Ag Stabile Emulsionen und Trockenpulver von Mischungen fettlöslicher Vitamine, deren Herstellung und Verwendung
US5994414A (en) 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
EP1249230B1 (de) * 2001-04-12 2003-11-05 Vesifact Ag Coenzym Q10 enthaltende Mikroemulsion-Prekonzentrate und Mikroemulsionen
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
EP1513499B1 (en) 2002-06-17 2012-01-18 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
US8628690B2 (en) 2004-02-23 2014-01-14 The Texas A&M University System Nanoemulsion compositions and methods of use thereof
EP1597973A1 (en) 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
US20060051462A1 (en) * 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
PT1959994T (pt) 2005-12-01 2017-11-30 Univ Massachusetts Lowell Nanoemulsões botulínicas
CN101011355B (zh) * 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
AU2007224006A1 (en) 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
ES2459876T3 (es) * 2007-11-28 2014-05-12 Commonwealth Scientific And Industrial Research Organisation Nanoemulsiones
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
EP2201937A1 (en) 2008-12-23 2010-06-30 Teva Pharmaceutical Industries Ltd. Formulations comprising vitamin D or derivatives thereof
EP2405895B1 (en) 2009-03-09 2021-05-12 Basf As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof
CN102470106B (zh) * 2009-05-18 2015-09-23 希格默伊德药业有限公司 包含油滴的组合物
KR20120050414A (ko) 2009-06-19 2012-05-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 약물의 나노분산액 및 그의 제조 방법
WO2011075623A1 (en) * 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
DK2544663T3 (en) * 2010-03-12 2018-04-16 Berg Llc INTRAVENOUS FORMULATIONS OF COENZYM Q10 (CoQ10) AND PROCEDURES FOR USING IT
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
SE536746C2 (sv) 2010-05-12 2014-07-08 Stora Enso Oyj En komposition innehållande mikrofibrillerad cellulosa och en process för tillverkning av en komposition
US8835509B2 (en) 2010-05-31 2014-09-16 Arbro Pharmaceuticals Ltd. Self emulsifying drug delivery system for a curcuminoid based composition
JP2013537185A (ja) 2010-09-08 2013-09-30 プロノヴァ・バイオファーマ・ノルゲ・アーエス 遊離酸の形のｅｐａおよびｄｈａを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物
WO2013008083A1 (en) 2011-07-13 2013-01-17 National Institute Of Pharmaceutical Education And Research (Niper) Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen
NZ596015A (en) 2011-10-26 2014-04-30 Anzamed Internat Ltd Method and composition for the treatment of pain and/or inflammation
GB201204377D0 (en) 2012-03-13 2012-04-25 Givaudan Sa Composition

Also Published As

Publication number Publication date
US20180177723A1 (en) 2018-06-28
AU2015246030B2 (en) 2020-03-12
US11458096B2 (en) 2022-10-04
IN2014CH01872A (es) 2015-05-08
AU2015246030A1 (en) 2016-11-24
EP3129002A2 (en) 2017-02-15
EP3129002A4 (en) 2017-11-08
WO2015155703A2 (en) 2015-10-15
EA201692044A1 (ru) 2017-04-28
EA038458B1 (ru) 2021-08-31
WO2015155703A3 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
MX2016013201A (es) Composicion y metodo para producir una nanoformulacion de bioactivos insolubles en agua en una base acuosa.
HK1225613A1 (zh) 赖谷胰岛素的稳定制剂
EP3267964A4 (en) Peg free stable low viscosity oil-in-water emulsion and use thereof
EP3215806A4 (en) 3d imaging, ranging, and/or tracking using active illumination and point spread function engineering
MX390001B (es) Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos.
PL2968306T3 (pl) Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
MX2015013894A (es) Composiciones de nanoparticulas novedosas.
JP2015110565A5 (es)
MX2015010312A (es) Metodos para tratamiento del melanoma.
CL2016002308A1 (es) Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer
MX2015012667A (es) Pigmento de dioxido de titanio y metodo de fabricacion.
BR112018070960A2 (pt) formulação parenteral de nimodipina estável
MX2016009577A (es) Composicion acuosa para recubrimiento de superficies y particulas modificadas.
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
MX387005B (es) Nanocápsula para la administración de un compuesto lipófilo y proceso de preparación de la misma.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
PT3197493T (pt) Métodos para reverter a caquexia e prolongar a sobrevivência que compreendem a administração de um modulador de gdf15 e um agente anti-carcinogénico
ZA201601668B (en) Cosmetic composition comprising a sulphonic polymer, a hydrophobic polysaccharide and a silicone surfactant
MX2019008845A (es) Metodos y sistemas para mejorar la estabilidad de la formulacion prevapor de un dispositivo de vapeo electronico.
MX385886B (es) Macromoleculas estrellas compatibles con tensoactivos.
IL266279B1 (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
AR101581A1 (es) Composición de colutorio
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
MX2016015208A (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: PULSE PHARMACEUTICALS PVT LTD